Stem cell injections are widely advertised — and frequently oversold. The honest evidence base for knee osteoarthritis is meaningful but specific. Here is what the data actually says.
Stem cell therapy for knee osteoarthritis is one of the most aggressively marketed interventions in clinics worldwide. Claims of "regrowing cartilage" remain ahead of the evidence. Class A academic centres in China — and credible centres elsewhere — present the data more honestly: meaningful benefit for selected patients, no substitute for arthroplasty in advanced disease.
The Marketing Problem
Stem cell therapy for knee osteoarthritis is one of the most aggressively marketed interventions in clinics worldwide. Claims of "regrowing cartilage" remain ahead of the evidence. Class A academic centres in China — and credible centres elsewhere — present the data more honestly: meaningful benefit for selected patients, no substitute for arthroplasty in advanced disease.
What's Actually Being Injected?
The term "stem cell" obscures what's typically delivered:
- Bone marrow aspirate concentrate (BMAC): autologous, drawn from iliac crest, contains a mixed population including some MSCs, growth factors, and platelets
- Adipose-derived stromal cells: autologous from liposuction sample, mixed cell population
- Cultured MSCs: expanded ex vivo, regulated as cell therapy in most jurisdictions
- Platelet-rich plasma (PRP): not a stem cell product, often offered alongside
Most "stem cell" knee injections in clinical practice are BMAC or adipose-derived rather than expanded MSC products.
What the Evidence Shows
For early-to-moderate knee OA (Kellgren-Lawrence grade 2–3), several randomised controlled trials and meta-analyses show meaningful pain and function improvement at 6–12 months from BMAC and PRP injections. Effect sizes are typically smaller than from total knee arthroplasty in advanced disease, but comparable to or better than hyaluronic acid injection.
For advanced (KL grade 4) bone-on-bone OA, evidence is weaker. Stem cell injection rarely changes the eventual need for arthroplasty in this stage; it sometimes provides bridging benefit.
What Honest Centres Tell You
Class A sports medicine departments — including Shanghai Ninth People's Hospital and Peking University Third Hospital — present this evidence frankly: realistic targets are pain reduction and function improvement, not cartilage regrowth. Outcomes are tracked at 6 and 12 months with standardised KOOS or WOMAC measures.
Pricing band for autologous BMAC at a Class A centre: USD 1,400–2,800 per knee, including consultation, imaging review, and follow-up. PRP courses (3 sessions) are USD 600–1,200.
Who Should Consider It?
Reasonable candidates: KL 2–3 OA, ongoing pain despite 3+ months of conservative care, no significant ligamentous instability, no advanced bone-on-bone changes. Take our KOOS-PS knee function self-test for a structured staging.
The Bigger Point
If a clinic promises cartilage regrowth or guarantees you'll avoid arthroplasty, walk away. Honest centres set expectations at pain and function — and that is enough to be valuable for the right patients.
Sources: 2024 American College of Rheumatology knee OA guidance; Cochrane reviews on PRP and BMAC for knee OA; partner-hospital sports medicine pricing 2026.